These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 2388646)

  • 1. Antiparkinsonian activity of a non-ergot dopamine agonist, CV 205-502, in patients with fluctuating Parkinson's disease.
    Poewe W; Luef G; Kleedorfer B; Emre M
    Mov Disord; 1990; 5(3):257-9. PubMed ID: 2388646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiparkinsonian activity of a single oral dose of PHNO.
    Grandas F; Quinn N; Critchley P; Rohan A; Marsden CD; Stahl SM
    Mov Disord; 1987; 2(1):47-51. PubMed ID: 2904120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CV 205-502: safety, tolerance to, and efficacy of increasing doses in patients with Parkinson's disease in a double-blind, placebo crossover study.
    Olanow CW; Werner EG; Gauger LL
    Clin Neuropharmacol; 1989 Dec; 12(6):490-7. PubMed ID: 2575014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiparkinsonian effects of BAM-1110, a novel ergoline derivative, in MPTP-treated cynomolgus monkeys.
    Kuno S; Mizuta E; Sakamoto H; Ichihara K; Nagasaka M
    Clin Neuropharmacol; 1998; 21(1):35-40. PubMed ID: 9579283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
    Smith L; De Salvia M; Jenner P; Marsden CD
    Mov Disord; 1996 Mar; 11(2):125-35. PubMed ID: 8684381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
    Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease.
    Temlett JA; Quinn NP; Jenner PG; Marsden CD; Pourcher E; Bonnet AM; Agid Y; Markstein R; Lataste X
    Mov Disord; 1989; 4(3):261-5. PubMed ID: 2571082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dermal application of lisuride on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset and on cases with Parkinson's disease].
    Nomoto M; Iwata S; Irifune M; Kaseda S; Osame M; Fukuda T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Jun; 18(3):81-7. PubMed ID: 9800199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset.
    Nomoto M; Stahl S; Jenner P; Marsden CD
    Mov Disord; 1987; 2(1):37-45. PubMed ID: 2904119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease].
    Kannari K; Kurahashi K; Tomiyama M; Maeda T; Arai A; Baba M; Suda T; Matsunaga M
    No To Shinkei; 2002 Feb; 54(2):133-7. PubMed ID: 11889759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK; Banerji T; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
    Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic delivery of catecholamines in the striatum attenuate parkinsonian symptoms and widen the therapeutic window of oral sinemet in rats.
    Lindner MD; Plone MA; Mullins TD; Winn SR; Chandonait SE; Stott JA; Blaney TJ; Sherman SS; Emerich DF
    Exp Neurol; 1997 May; 145(1):130-40. PubMed ID: 9184116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.
    Greenamyre JT; Eller RV; Zhang Z; Ovadia A; Kurlan R; Gash DM
    Ann Neurol; 1994 Jun; 35(6):655-61. PubMed ID: 8210221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
    Suwantamee J; Nidhinandana S; Srisuwananukorn S; Laptikultham S; Pisarnpong A; Chankrachang S; Bundhukul A
    J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease.
    McCall RB; Lookingland KJ; Bédard PJ; Huff RM
    J Pharmacol Exp Ther; 2005 Sep; 314(3):1248-56. PubMed ID: 15980060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PHNO, a novel dopamine agonist, in animal models of parkinsonism.
    Koller W; Herbster G; Gordon J
    Mov Disord; 1987; 2(3):193-9. PubMed ID: 2904649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.